<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01717859</url>
  </required_header>
  <id_info>
    <org_study_id>ML28542</org_study_id>
    <secondary_id>ML28542</secondary_id>
    <nct_id>NCT01717859</nct_id>
  </id_info>
  <brief_title>Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab</brief_title>
  <acronym>RASTS</acronym>
  <official_title>Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if a change in inflammation or baseline
      inflammation seen on the ultrasound is a good indicator of how rheumatoid arthritis patients
      respond to TCZ 4mg/kg and whether early prediction of dose escalation is possible by
      utilizing ultrasound inflammatory measures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline to month 3 change in total power Doppler synovitis score of 30 joints (range 0-90)</measure>
    <time_frame>Baseline, 3 Month</time_frame>
    <description>30 joints will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline to month 3 change in total B-mode synovial hypertrophy score of 30 joints (range 0-90)</measure>
    <time_frame>Baseline, 3 Month</time_frame>
    <description>30 joints will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to month 3 change in composite of power Doppler and synovial hypertrophy of 30 joints (range 0-180)</measure>
    <time_frame>Baseline, 3 Month</time_frame>
    <description>30 joints will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to month 3 change in MBDA</measure>
    <time_frame>Baseline, 3 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to month 3 change in DAS28ESR</measure>
    <time_frame>Baseline, 3 month</time_frame>
    <description>28 joint will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to month 3 change in CDAI</measure>
    <time_frame>Baseline, 3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will receive tocilizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>All subjects will start at 4mg/kg. After 3 months, if DAS28 &gt; 3.2, dosage will be escalated to 8 mg/kg.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patient must meet 1987 ACR criteria,

          2. Age &gt; 18 years of age,

          3. Baseline DAS28/ESR&gt;4.4,

          4. Stable concomitant DMARDs,

          5. Stable prednisone &lt;10mg or equivalent, and

          6. Power Doppler score of &gt;=10
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veena Ranganath, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA David Geffen School of Medicine, Division of Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dr. Veena Ranganath</investigator_full_name>
    <investigator_title>M.D., M.S., Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

